DUBLIN--(BUSINESS WIRE)--The "Helicobacter Pylori Infections - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Helicobacter Pylori Infections - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Helicobacter Pylori Infections development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Helicobacter Pylori Infections Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
Companies Mentioned
- Daewoong Pharmaceutical
- EpiVax
- ImevaX
- ImmunoBiology Limited
- RedHill Biopharma Ltd
- Sequella
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4zswk9/helicobacter?w=4
